Ian R. Rifkin, MD, PhD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Nephrology Section

MBBCh, University of the Witwatersrand
PhD, University of Cambridge
MSc, University of London



Expertise includes: Immunology; Autoimmunity; Systemic lupus erythematosus; and Nephrology.

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Division of Graduate Medical Sciences


Assistant Professor
Boston University School of Medicine
Microbiology


Active Staff Privileges
Boston Medical Center
Medicine




Tool-like receptors in Systemic Autoimmune Disease
02/11/2010 - 06/30/2014 (PI)
University of Massachusetts, Worcester NIH NIAMS
5P01AR050256-11

Role of Toll-like Receptors in Dendritic Cell Activation by Chromatin-Containing Immune Complexes
08/01/2002 - 01/31/2007 (PI)
The Lupus Research Institute Inc

Toll-like Receptors in the Pathogenesis of SLE and Immunologically-Mediated Renal Disease
04/01/2002 - 12/31/2006 (Co-PI)
Coley Pharmaceutical Group


The role of innate immune system mediators and pathways in SLE pathogenesis
12/21/2015 - 12/20/2018 (PI)
Merck

Evaluation of antibodies for the treatment of autoimmune diseases
03/01/2016 - 04/30/2018 (PI)
Chugai Pharmaceutical, Co., Ltd.

Immunomodulator identification in systemic lupus erythematosus
12/02/2015 - 12/01/2017 (PI)
Merck

Evaluating impact of Biogen IRAK 4 inhibitors on metabolism and generation of human plasmacytoid den
09/23/2013 - 09/30/2016 (PI)
Biogen, Inc

SLE-immune complex-mediated inflammatory cell activation: regulation by IRF5 and new effector discov
11/01/2012 - 08/31/2015 (PI)
Kyowa Hakko Kirin Co.

IRAK4 Kinase and Autoimmune Disease
10/01/2011 - 09/30/2013 (PI)
Biogen, Inc

Comparison of Mofetil and Azathioprine in a murine model of accelerated atherosclerosis in systemic
04/15/2007 - 12/31/2012 (PI)
Aspreva Pharmaceuticals

Adiponectin and Adiponectin Receptors in Lupus and Lupus Atherosclerosis
02/01/2010 - 11/30/2012 (PI)
Alliance for Lupus Research

PPAR Gamma and Adiponectin in Lupus Nephritis and Atherosclerosis
02/01/2008 - 01/31/2010 (PI)
Alliance for Lupus Research

Toll-like Receptors in the Pathogenisis
07/01/2002 - 06/30/2005 (PI)
National Kidney Fdtn

Showing 10 of 12 results. Show All Results


Yr Title Project-Sub Proj Pubs
2013 THE ROLE OF INTERFERON REGULATORY FACTOR 5 IN THE PATHOGENESIS OF SLE 5P01AR050256-11-6674 41
2012 THE ROLE OF INTERFERON REGULATORY FACTOR 5 IN THE PATHOGENESIS OF SLE 5P01AR050256-10-6674 41
2011 THE ROLE OF INTERFERON REGULATORY FACTOR 5 IN THE PATHOGENESIS OF SLE 5P01AR050256-09-6674 41
2010 THE ROLE OF INTERFERON REGULATORY FACTOR 5 IN THE PATHOGENESIS OF SLE 5P01AR050256-08-6674 41
2009 THE ROLE OF INTERFERON REGULATORY FACTOR 5 IN THE PATHOGENESIS OF SLE 2P01AR050256-06-6674 41
2009 THE ROLE OF INTERFERON REGULATORY FACTOR 5 IN THE PATHOGENESIS OF SLE 7P01AR050256-07-6674 41
2008 TLR-dependent Dendritic Cell Activation in SLE 5P01AR050256-05-2 41
2008 Animal Core 5P01AR050256-05-9004 41
2007 Core C (BU) 5P01AR050256-04-9003 41
2007 TLR-Dependent Dendritic Cell Activation in SLE 5P01AR050256-04-2 41
Showing 10 of 18 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Choo MK, Sano Y, Kim C, Yasuda K, Li XD, Lin X, Stenzel-Poore M, Alexopoulou L, Ghosh S, Latz E, Rifkin IR, Chen ZJ, Stewart GC, Chong H, Park JM. TLR sensing of bacterial spore-associated RNA triggers host immune responses with detrimental effects. J Exp Med. 2017 May 01; 214(5):1297-1311.View Related Profiles. PMID: 28400473; DOI: 10.1084/jem.20161141;.
  2. Das A, Heesters BA, Bialas A, O''Flynn J, Rifkin IR, Ochando J, Mittereder N, Carlesso G, Herbst R, Carroll MC. Follicular Dendritic Cell Activation by TLR Ligands Promotes Autoreactive B Cell Responses. Immunity. 2017 Jan 17; 46(1):106-119. PMID: 28099860; DOI: 10.1016/j.immuni.2016.12.014;.
  3. Duffau P, Menn-Josephy H, Cuda CM, Dominguez S, Aprahamian TR, Watkins AA, Yasuda K, Monach P, Lafyatis R, Rice LM, Kenneth Haines G, Gravallese EM, Baum R, Richez C, Perlman H, Bonegio RG, Rifkin IR. Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model. Arthritis Rheumatol. 2015 Dec; 67(12):3146-57.View Related Profiles. PMID: 26315890; PMCID: PMC4661118; DOI: 10.1002/art.39321;.
  4. Aprahamian TR, Zhong X, Amir S, Binder CJ, Chiang LK, Al-Riyami L, Gharakhanian R, Harnett MM, Harnett W, Rifkin IR. The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model. Int J Parasitol. 2015 Mar; 45(4):203-7.View Related Profiles. PMID: 25666929; PMCID: PMC4355381; DOI: 10.1016/j.ijpara.2014.12.006;.
  5. Watkins AA, Yasuda K, Wilson GE, Aprahamian T, Xie Y, Maganto-Garcia E, Shukla P, Oberlander L, Laskow B, Menn-Josephy H, Wu Y, Duffau P, Fried SK, Lichtman AH, Bonegio RG, Rifkin IR. IRF5 deficiency ameliorates lupus but promotes atherosclerosis and metabolic dysfunction in a mouse model of lupus-associated atherosclerosis. J Immunol. 2015 Feb 15; 194(4):1467-79.View Related Profiles. PMID: 25595782; PMCID: PMC4323680; DOI: 10.4049/jimmunol.1402807;.
  6. Mathes AL, Rice L, Affandi AJ, DiMarzio M, Rifkin IR, Stifano G, Christmann RB, Lafyatis R. CpGB DNA activates dermal macrophages and specifically recruits inflammatory monocytes into the skin. Exp Dermatol. 2015 Feb; 24(2):133-9.View Related Profiles. PMID: 25425469; PMCID: PMC4474603; DOI: 10.1111/exd.12603;.
  7. Tan Y, Watkins AA, Freeman BB, Meyers JA, Rifkin IR, Lerner A. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. J Immunol. 2015 Jan 1; 194(1):101-12.View Related Profiles. PMID: 25416804; PMCID: PMC4333002.
  8. Ericson JA, Duffau P, Yasuda K, Ortiz-Lopez A, Rothamel K, Rifkin IR, Monach PA. Gene expression during the generation and activation of mouse neutrophils: implication of novel functional and regulatory pathways. PLoS One. 2014; 9(10):e108553.View Related Profiles. PMID: 25279834; PMCID: PMC4184787; DOI: 10.1371/journal.pone.0108553;.
  9. Yasuda K, Watkins AA, Kochar GS, Wilson GE, Laskow B, Richez C, Bonegio RG, Rifkin IR. Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2. PLoS One. 2014; 9(7):e103478.View Related Profiles. PMID: 25076492; PMCID: PMC4116215; DOI: 10.1371/journal.pone.0103478;.
  10. Aprahamian TR, Bonegio RG, Weitzner Z, Gharakhanian R, Rifkin IR. Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus. Immunology. 2014 Jul; 142(3):363-73.View Related Profiles. PMID: 24456224; PMCID: PMC4080952; DOI: 10.1111/imm.12256;.
Showing 10 of 55 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 51 publications over 22 distinct years, with a maximum of 6 publications in 2009

YearPublications
19871
19911
19922
19932
19941
19951
19961
19981
19991
20002
20021
20032
20044
20052
20065
20072
20096
20103
20132
20144
20155
20172
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

atherosclerosis
Autoimmunity
interferon regulatory factors
systemic lupus erythematosus
Toll like receptors
Contact for Mentoring:


650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Rifkin's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department